haloperidol has been researched along with pf-2545920 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chappie, TA; Helal, CJ; Hou, X | 1 |
| Breslin, MJ; Coleman, PJ; Cox, CD; Fandozzi, C; Fuerst, J; Hill, N; Huszar, S; Kandebo, M; Kim, SH; Ma, B; McGaughey, G; Raheem, IT; Renger, JJ; Schreier, JD; Sharma, S; Smith, S; Uslaner, J; Yan, Y | 1 |
2 other study(ies) available for haloperidol and pf-2545920
| Article | Year |
|---|---|
Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
Topics: Animals; Cyclic AMP; Cyclic GMP; Humans; Hydrolysis; Mice; Models, Molecular; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats | 2012 |
Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Topics: Administration, Oral; Animals; Cyclic GMP; Dose-Response Relationship, Drug; Drug Discovery; Humans; Molecular Structure; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridines; Pyrimidines; Rats; Schizophrenia; Structure-Activity Relationship | 2012 |